Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM TrialMarcello Tiseo, Andrea Ardizzoni, Luca Boni et al.|Journal of Clinical Oncology|2017Cited by 186
Neutrophil-to-Lymphocyte Ratio Is a Major Prognostic Factor in Non-small Cell Lung Carcinoma Patients Undergoing First Line Immunotherapy With PembrolizumabFrancesco Jacopo Romano, Ferdinando Riccardi, I Giacobbe et al.|Cancer Diagnosis & Prognosis|2022Cited by 28
Italian Multicenter Phase III Randomized Study of Cisplatin–Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive Stage Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the GOIRC-AIFA FARM6PMFJM TrialMarcello Tiseo, Andrea Ardizzoni, Luca Boni et al.|Clinical Lung Cancer|2014Cited by 19
Therapy innovation for the treatment of pancreatic neuroendocrine tumorsFerdinando Riccardi, Giacomo Cartenì, Mimma Rizzo et al.|Expert Opinion on Therapeutic Targets|2012Cited by 8
Horner’s syndrome: An unusual presentation of metastatic disease in breast cancerMaria Giuseppa Vitale, Giacomo Cartenì, Ferdinando Riccardi et al.|International Journal of Immunopathology and Pharmacology|2015Cited by 4